Neurology News

Avidity Biosciences Inc. has announced positive data in healthy volunteers from its ongoing phase 1/2 clinical trial of a proprietary monoclonal antibody to treat Duchenne muscular dystrophy mutations amenable to exon 44 skipping.

A clinical-stage biopharmaceutical company has announced positive findings from the exploratory SHAPE phase 2 clinical trial to evaluate fosgonimeton in those with Parkinson’s disease dementia and dementia with Lewy bodies.

Delix Therapeutics announced it has received a $320,000 grant from NIH’s National Institute on Drug Abuse to advance its novel, non-hallucinogenic neuroplastogen for treatment of substance use disorders, including opioid and stimulant use.

A company specializing in treatment for neurodegenerative diseases announced positive topline data from a phase 2b clinical trial of a novel, extended release oral fixed-dose therapeutic to treat amyotrophic lateral sclerosis.

ORLANDO — While effective medications for epilepsy exist, scientific advancement requires that future gene-targeting therapies or cures benefit the largest number of patients while overcoming several barriers, according to a presentation.

A company specializing in therapeutics for rare and neurodegenerative diseases has announced a partnership with a provider of innovative solutions in early-stage drug discovery to develop a BRD9 inhibitor to treat Huntington’s disease.

Adolescents fell asleep an average of 11 minutes later each night for every hour they used a screen device to communicate with friends during the day, according to a study published in the Journal of Adolescent Health.

AbbVie Inc. has acquired Cerevel Therapeutics and its pipeline of clinical stage and preclinical neuroscience candidates in development to address conditions such as Parkinson’s disease, schizophrenia and mood disorders.

Patients with obstructive sleep apnea who used positive airway pressure consistently for 4 hours or more per night over 3 years had lower health care costs than patients with infrequent use, according to results published in CHEST.

ORLANDO — Although effective treatments have been established for those with epilepsy, there is a need for more and novel therapies, which face barriers of efficacy and access, according to a presenter.